On 3rd December 2018, Regeneus Limited (ASX: RGS), an Australian regenerative medicine company, has been granted a Chinese patent “Biomarkers for cell therapy”-Application No. 201480060270 by State Intellectual Property Office of China. With protection rights till 2033 in China, this will provide license for company’s leading Progenza stem cell therapy technology, for the treatment of osteoarthritis and other musculoskeletal disorders. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]
The patent aims at using mesenchymal stem cell (MSC) therapeutics along with biomarker for monitoring and treatment of disease in patients having inflammatory conditions such as Crohn’s disease, cardiovascular disease and osteoarthritis. Under the present regime effective December 2017, cell therapy products need to go through two clinical phases in China- the first phase focused on safety and the subsequent confirmatory phase to demonstrate probable efficacy. These new cell products will be available for government reimbursement.
Progenza is Regeneus’ leading cell therapy for the treatment of knee osteoarthritis and other musculoskeletal conditions. The firm has reported significance success and positive results this year, from its Phase 1 STEP (Safety, Tolerability and Efficacy) trial of Progenza for knee osteoarthritis. The test depicts that a single dose insertion into the knee of patients appeared safe.
In October 2018, the clinical-stage regenerative medicine company was granted European patent entitled “Therapeutics using adipose cells and cell secretions”, which will provide the firm critical rights for Progenza until 2032 in up to 38 European member states. The patent will join parallel patents already obtained in other advanced nations, providing significant protection of the firm’s technology and R&D to the Progenza platform. In February 2018, Progenza was associated with an Advanced Therapy Medicinal Product (ATMP) classification by the Committee for European Commission.
In addition, the firm was issued Progenza patent Office ‘Therapeutics using adipose cells and cell secretions’ from United States Patent Office in July 2018, enabling the firm to enjoy patent protection and commercial rights till 2032.
Regeneus has also tapped Japanese economy for significant patent protection. In February 2018, it was successful in obtaining Japanese patent grant titled ‘Vaccines for the treatment or prevention of cancer and compositions for enhancing vaccine efficacy’ – Application No. 2015-549902, valid till 2033. The protection aims at cancer vaccine utilization for humans and animals.
Enjoying increasing number of patent protection for its key stem cell technology across the globe, Regeneus stock price has shown an upward trend from stock price level of $ 0.125 in the year beginning, peaking to $ 0.235 as well in between, with last close price of $ 0.210 as of 4 December 2018, up 7.7% on intraday levels.
There is an increasing demand all over the world for broad range of regenerative cell therapies and medical treatments. With over 80 patents across varied product lines and in some of the world’s largest regenerative therapy markets, Regeneus enjoys a significant protection of its Intellectual Property, medical research and treatment in a competitive environment of global commercialization, thereby stimulating healthy research in human and animal health care stem cell therapies. The firm aims at achieving further significant milestones in patent grants in near future, by spreading its geographical reach to other key markets.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.